2022 DOI: 10.1016/j.cmet.2022.07.013 PMID: 35985340 Read on PubMed The Lancet LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial Urva S, Coskun T, Loh MT, et al
kvue } : CS1 maint: url-status (link) "Policy manual" (PDF)
Those using semaglutide primarily for weight loss might consider dose adjustments if menstrual disruptions significantly impact quality of life
Patients pay about $100$450 monthly for compounded semaglutide, compared with list prices of roughly $1,000-$1,400 for Nordisk products.